Use Sativex as an adjunct
when patients’ first-line oral
anti-spasticity medications
are not enough1–3

GW
Pharmaceuticals
covers the cost of
treatment for the
4-week trial so
the NHS only has
to pay for
patients who find
it effective

Pay-for-responders scheme
Image
icons

NICE re-evaluated Sativex in 2019 and recognised the benefits it can offer to patients2

NICE recommended Sativex in conjunction with GW Pharmaceuticals’ pay-for-responders scheme2

 

Continued funding for patients who respond to Sativex must be formally agreed at a local level before treatment starts

Image
graph
Image
graph-mobile

View the NICE and AWMSG recommendations
on the use of Sativex:

 

 

Read the terms and conditions of the pay-for-
responders scheme:

 

Download the pay-for-responders scheme application forms if you wish to participate in the scheme: